Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1659-1661

  Cacheux, W ^a   Boisserie, T ^a   Staudacher, L ^a   Vignaux, O ^a   Dousset, B ^a   Soubrane, O ^a   Terris, B ^a   Mateus, C ^a   Chaussade, S ^a   Goldwasser, Francois ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; METASTASIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 50849089255     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn540     Document Type: Article

References (5)

1. Mancuso MR, Davis R, Norberg SM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116(10): 2610-2621.
2. Tournigand C, André T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOP study J Clin Oncol 2004; 22(2): 229-237.
3. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 2006; 93(12): 1456-1463.
4. Matsumoto Y, Freund KB, Peiretti E. Rebound macular edema following bevacizumab therapy for retinal veinous occlusive disease. Retina 2007; 27(4): 426-431.
5. Belizon A, Balik E, Feingold DL. Major abdominal surgery increases plasma levels of vascular endothelial growth factor: Open more so than minimally invasive methods. Ann Surg 2006; 244(5): 792-798.